Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EBP11

Peptide · developed by Eli Lilly and Company

Phase 1 Most advanced trial (none active)
1 Registered trials

What is EBP11?

EBP11 is the 1-34 fragment of human parathyroid hormone, a peptide that acts as an agonist at the parathyroid hormone receptor. It is studied in hypoparathyroidism, osteoporosis and bone fractures.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
hPTH(1-34)
Drug type
Peptide
Therapy area
Endocrine, Musculoskeletal
Developer
Eli Lilly and Company
In trials of
ENTX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05965167 Phase 1 Hypoparathyroidism Completed ENTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fractures, BoneHypoparathyroidismOsteoporosisOther Disease

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.